Modeling the Impact of Biomarker-Guided Versus ASCVD Risk-Guided Drug Treatment in US Adults With Stage 1 Hypertension: The National Health and Nutrition Examination Survey, 1999 to 2004.
Kathryn E FotiDan WangOlive TangNatalie R DayaYvonne Commodore-MensahStephen P JuraschekRobert H ChristensonElizabeth SelvinJohn W McEvoyPublished in: Hypertension (Dallas, Tex. : 1979) (2024)
Cardiac biomarkers may be more selective for informing risk-based treatment decisions in stage 1 hypertension, particularly among adults aged ≥65 years.